Fulvestrant Selective estrogen receptor downregulators (SERDs)
systematic review meta-analysis network meta-analysis
 

Faslodex - ZM-182780 - ZM 182780 - ICI-182780 - ICI 182780      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultprogression (Time to progression TTP) progression or death (progression free survival PFS)

advanced breast cancer (metastatic)  

GEICAM/2006-10    NCTfulvestrant + anastrozoleanastrozole HER-2 negative HR positive postmenopausal Risk of bias -
FACT (Bergh), 2012      NCTfulvestrant + anastrozoleanastrozole first line of endocrine therapy HR positive postmenopausal negative-1%-1%
Mehta(SWOG-S0226), 2012      NCTfulvestrant + anastrozoleanastrozole HR positive suggesting-20%-20%
Xu et al., 2011      NCTfulvestrant 250mganastrozole HR positive postmenopausal Low risk of bias -
0021 (Osborne), 2002      NCTfulvestrant 250mganastrozole postmenopausal Low risk of bias negative-8%
0020 (Howell), 2002     fulvestrant 250mganastrozoleRisk of bias negative-2%
FIRST (Robertson), 2010    NCTfulvestrant 500mganastrozole first line of endocrine therapy postmenopausal suggesting-34%
9238UK/0005 (fluvestrant alone)    NCTfluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy Low risk of bias -
SoFEa (Johnston) fluvestrant alone, 2012      NCTfluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy -
9238UK/0005 (combination)    NCTfulvestrant + anastrozoleexemestane postmenopausal previously treated with endocrine therapy Low risk of bias -
SoFEa (Johnston) combination, 2012      NCTfulvestrant + anastrozoleexemestane HR positive postmenopausal previously treated with endocrine therapy negative-5%-5%
EFECT (Chia)    NCTfulvestrant 250mgexemestane HR positive postmenopausal Low risk of bias negative-4%
D6997L00021    NCTfulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy Low risk of bias -
CONFIRM (Di Leo), 2010      NCTfulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy Low risk of bias -
FINDER 1 (Ohno), 2010     fulvestrant 500mgfulvestrant 250mg postmenopausal -
FINDER 2, 2010      NCTfulvestrant 500mgfulvestrant 250mg postmenopausal previously treated with endocrine therapy Exploratory -
9238IL/0025    NCTfulvestrant 250mgtamoxifen first line of endocrine therapy Low risk of bias -
0025 (Howell), 2004     fulvestrant 250mgtamoxifen previously treated with endocrine therapy Low risk of bias negative18%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons